FDA says current dose of GSK-Vir COVID therapy unlikely to work against BA.2 variant | Reuters
The U.S. health regulator said on Friday the current authorized dose of GlaxoSmithKline and Vir Biotechnology's COVID-19 antibody therapy is unlikely to be effective against the Omicron BA.2 variant.
